摘要
非酒精性脂肪肝(NAFLD)是一种代谢相关性,以肝细胞脂肪变性为主要特征的疾病。随着近几十年来人民生活水平的提高,在我国NAFLD的患病率达到了6%~27%,已取代慢性乙型肝炎成为我国第一大慢性肝病,且目前正朝着低龄化和迅速上升的态势发展,严重威胁人类健康。至今为止,除了控制血糖和血脂以及减肥等针对原发病和危险因素的治疗方式外,暂无明确的药物治疗方法。而近年来由于对肠–肝轴的认识越来越深,以及对肠道菌群在NAFLD发生机理中的作用了解越来越多,益生菌防治NAFLD的研究也随之增多。本综述重点对肠道益生菌的新疗法在NAFLD治疗中的研究进展进行总结。
Nonalcoholic fatty liver disease (NAFLD) is a metabolic related disease characterized by hepatocyte steatosis. With the improvement of people’s living standards in recent decades, the prevalence of NAFLD in China has reached 6%~27%, which has replaced chronic hepatitis B and become the largest chronic liver disease in China. At present, it is developing towards younger age and rising rapidly, which has seriously threatened human health. So far, there is no clear drug treatment ex-cept for the treatment of primary disease and risk factors such as blood glucose and blood lipid control and weight loss. In recent years, due to the deeper understanding of the gut liver axis and the role of intestinal flora in the pathogenesis of NAFLD, the research on the prevention and treat-ment of NAFLD by probiotics has also increased. This review focuses on the research progress of new therapies of intestinal probiotics in the treatment of NAFLD.
出处
《临床医学进展》
2022年第8期7249-7255,共7页
Advances in Clinical Medicine
